Bacterial oncolytic therapy as a novel approach for cancer treatment in humans

Sikander Ali , Asma Mehboob , Muhammad Arshad , Khayala Mammadova , Muhammad Usman Ahmad
{"title":"Bacterial oncolytic therapy as a novel approach for cancer treatment in humans","authors":"Sikander Ali ,&nbsp;Asma Mehboob ,&nbsp;Muhammad Arshad ,&nbsp;Khayala Mammadova ,&nbsp;Muhammad Usman Ahmad","doi":"10.1016/j.ctarc.2025.100892","DOIUrl":null,"url":null,"abstract":"<div><div>Cancer is the leading cause of death worldwide. Conventional cancer therapies, such as chemotherapy, radiation therapy, and immunotherapy often face certain limitations in treating cancer, such as toxicity, resistance, and ineffectiveness against different cancer types. Therefore, there is an urgent need for alternative treatment strategies. One emerging area of interest is the use of bacterial oncolytic therapy. It employs the natural properties of bacteria to target and destroy cancer cells. Both natural and genetically modified bacterial strains have shown potential to target the hypoxic regions of tumors, which are often resistant to conventional treatments. These bacteria also produce therapeutic molecules that induce cancer cell death. Furthermore, they can stimulate immune responses against tumors, making them helpful in developing cancer vaccines and exploiting antitumor bacterial metabolites. The versatility of bacterial oncolytic therapy extends beyond direct tumor targeting. It can be combined with conventional methods to enhance overall treatment efficacy. Moreover, bacteria can also serve as delivery vehicles for anticancer drugs, ensuring more precise targeting and reduced side effects. Different bacterial genera, such as <em>Salmonella, Clostridium, Bifidobacterium,</em> and <em>Listeria</em>, have demonstrated significant anticancer potential. This review aims to provide a comprehensive overview of bacterial oncolytic therapy, exploring its various applications and potential in conjunction with traditional cancer treatments.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100892"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer is the leading cause of death worldwide. Conventional cancer therapies, such as chemotherapy, radiation therapy, and immunotherapy often face certain limitations in treating cancer, such as toxicity, resistance, and ineffectiveness against different cancer types. Therefore, there is an urgent need for alternative treatment strategies. One emerging area of interest is the use of bacterial oncolytic therapy. It employs the natural properties of bacteria to target and destroy cancer cells. Both natural and genetically modified bacterial strains have shown potential to target the hypoxic regions of tumors, which are often resistant to conventional treatments. These bacteria also produce therapeutic molecules that induce cancer cell death. Furthermore, they can stimulate immune responses against tumors, making them helpful in developing cancer vaccines and exploiting antitumor bacterial metabolites. The versatility of bacterial oncolytic therapy extends beyond direct tumor targeting. It can be combined with conventional methods to enhance overall treatment efficacy. Moreover, bacteria can also serve as delivery vehicles for anticancer drugs, ensuring more precise targeting and reduced side effects. Different bacterial genera, such as Salmonella, Clostridium, Bifidobacterium, and Listeria, have demonstrated significant anticancer potential. This review aims to provide a comprehensive overview of bacterial oncolytic therapy, exploring its various applications and potential in conjunction with traditional cancer treatments.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
期刊最新文献
Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway. WITHDRAWN: Association between Prostatic Calculi and Prostate Cancer. Whole exome sequencing of low risk endometrial cancer patients with isolated local recurrences Relationship between p53 protein and ER, PR status in breast cancer tissue Evaluation of recurrence and survival in multifocal versus unifocal breast cancer patients at a tertiary center: A case-control study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1